Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and ...

Clinician-scientists analyzed samples from patients' airways and blood, finding distinct changes in children with severe cases of RSV, including an increase in the number of natural killer (NK) cells ...

COVID-19, influenza and RSV are the main threats between October and May. There are vaccines for all three viruses, so you ...

In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both.

According to the CDC, 100,000 older adults a year end up in the hospital, and about 10,000 older adults die from RSV every ...

Adults who are at risk of severe RSV are 75 years or older. Also, people between 60 and 74 years old who have chronic health ...

The NHS is also offering for the first time a vaccination against respiratory syncytial virus (RSV), a common cause of coughs ...

Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial ...

As the days grow cooler, families across Utah are reminded that respiratory viruses, particularly Respiratory Syncytial Virus ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infantsParis, October 9, ...